5VM
5AM Venture Management Portfolio holdings
AUM
$260M
This Quarter Return
+12.56%
1 Year Return
+3.76%
3 Year Return
+144.87%
5 Year Return
+32.61%
10 Year Return
–
AUM
$401M
AUM Growth
+$401M
(+2.7%)
Cap. Flow
+$15.2M
Cap. Flow
% of AUM
3.78%
Top 10 Holdings %
Top 10 Hldgs %
79.05%
Holding
28
New
4
Increased
3
Reduced
1
Closed
4
Top Buys
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$16.3M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
$13.8M |
| 3 |
Celldex Therapeutics
CLDX
|
$10.5M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$6.96M |
| 5 |
Viking Therapeutics
VKTX
|
$3.81M |
Top Sells
| 1 |
IDEAYA Biosciences
IDYA
|
$11.9M |
| 2 |
FibroGen
FGEN
|
$10.8M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$6.92M |
| 4 |
Disc Medicine
IRON
|
$4.44M |
| 5 |
PEAR
Pear Therapeutics, Inc. Class A Common Stock
PEAR
|
$4.27M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Enliven Therapeutics
ELVN
$1.2B
| $118M | 29.48% |
5,798,475
| – | – |
|
2
Entrada Therapeutics
TRDA
$208M
| $66.7M | 16.63% |
4,408,379
| – | – |
|
|
3
Disc Medicine
IRON
$2.07B
| $21.7M | 5.4% |
488,442
-100,000
| -17% | -$4.44M |
|
4
Rallybio
RLYB
$22.4M
| $20.5M | 5.12% |
3,630,724
| – | – |
|
5
Vor Biopharma
VOR
$250M
| $19.7M | 4.9% |
6,361,723
| – | – |
|
|
6
MoonLake Immunotherapeutics
MLTX
$3.54B
| $18.2M | 4.54% |
357,486
+318,630
| +820% | +$16.3M |
|
7
Crinetics Pharmaceuticals
CRNX
$2.92B
| $15.5M | 3.87% |
862,286
| – | – |
|
|
8
Zentalis Pharmaceuticals
ZNTL
$122M
| $13.8M | 3.44% |
+490,000
| New | +$13.8M |
|
9
scPharmaceuticals
SCPH
$295M
| $12.2M | 3.05% |
1,200,647
| – | – |
|
|
10
Celldex Therapeutics
CLDX
$1.47B
| $10.5M | 2.62% |
+310,270
| New | +$10.5M |
|
|
11
Viking Therapeutics
VKTX
$3.04B
| $9.48M | 2.36% |
585,000
+235,000
| +67% | +$3.81M |
|
12
Cogent Biosciences
COGT
$1.69B
| $9.36M | 2.33% |
790,440
| – | – |
|
13
Pharvaris
PHVS
$1.39B
| $8.9M | 2.22% |
587,600
| – | – |
|
14
Arvinas
ARVN
$568M
| $7.94M | 1.98% |
320,000
| – | – |
|
15
Avidity Biosciences
RNA
$5.99B
| $7.38M | 1.84% |
665,555
| – | – |
|
16
AnaptysBio
ANAB
$569M
| $7.28M | 1.81% |
357,733
| – | – |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.96M | 1.73% |
+192,500
| New | +$6.96M |
|
18
Viridian Therapeutics
VRDN
$1.5B
| $6.66M | 1.66% |
280,000
| – | – |
|
|
SPRB
19
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $5.08M | 1.27% |
2,364,000
| – | – |
|
20
Mersana Therapeutics
MRSN
$36.5M
| $4.29M | 1.07% |
1,305,000
+120,000
| +10% | +$395K |
|
21
Q32 Bio
QTTB
$20.9M
| $4.01M | 1% |
4,535,919
| – | – |
|
|
IMPL
22
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $3.66M | 0.91% |
2,884,791
| – | – |
|
23
GH Research
GHRS
$837M
| $1.8M | 0.45% |
+152,022
| New | +$1.8M |
|
24
Cidara Therapeutics
CDTX
$1.66B
| $1.28M | 0.32% |
1,134,511
| – | – |
|
|
25
FibroGen
FGEN
$47.8M
| – | – |
-579,434
| Closed | -$10.8M |
|